证券代码：300430 证券简称：诚益通 公告编号：2025-050 北京诚益通控制技术集团股份有限公司 关于使用闲置自有资金进行委托理财的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京诚益通控制技术集团股份有限公司（以下简称"公司"）于 2025 年 5 月 14 日召开 2024 年度股东大会，审议通过了《关于使用闲置自有资金进行委托 理财的议案》。同意公司及子公司使用额度不超过 1 亿元人民币的闲置自有资金 进行委托理财，购买低风险、流动性好、安全性高的理财产品，上述额度可由公 司及子公司共同滚动使用，并授权公司管理层具体实施相关事宜，期限自 2024 年度股东大会审议通过之日起至 2025 年度股东大会召开之日止，同意对相关理 财的资金情况每月定期披露进展。 近日公司及子公司使用闲置自有资金在授权范围内购买了理财产品，现将相 关事项公告如下： | 投资主体 | 受托 | 关联 | 产品名称 | 产品 | 委托理财金 | 起息日 | 到期日 | 预期年 化收益 | | --- | --- | --- | --- | --- | --- | ...

证券代码：300430 证券简称：诚益通 公告编号：2025-049 北京诚益通控制技术集团股份有限公司 第五届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 北京诚益通控制技术集团股份有限公司（以下简称"公司"）第五届董事会 第十三次会议通知已于 2025 年 10 月 18 日以电子邮件、专人送达等方式发出， 并于 2025 年 10 月 29 日在公司会议室召开。本次会议应出席董事 9 名，实际参 会董事 9 名，公司高级管理人员列席了会议。会议的召开符合法律、行政法规、 部门规章及《公司章程》的规定，合法有效。 二、董事会会议审议情况 审议通过《关于公司<2025 年第三季度报告>的议案》 三、备查文件 《公司第五届董事会第十三次会议决议》。 特此公告。 北京诚益通控制技术集团股份有限公司 董事会 2025 年 10 月 30 日 具体内容详见同日披露在中国证监会指定创业板信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）上发布的公告。 表决结果：同意票 9 票，反对票 0 ...

Financial Performance - The company's operating revenue for Q3 2025 reached ¥225,215,865.12, representing a 48.67% increase year-over-year[5] - Net profit attributable to shareholders was ¥16,650,860.58, up 14.92% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses was ¥15,248,404.64, reflecting a 42.22% increase year-over-year[5] - Total operating revenue for the current period is RMB 633,187,224.46, a decrease of 20.5% compared to RMB 795,475,666.50 in the previous period[35] - Operating profit declined to ¥52,028,504.62 from ¥105,503,061.12, representing a decrease of about 50.7%[36] - Net profit attributable to shareholders decreased to ¥67,828,406.85 from ¥98,057,162.61, a decline of approximately 30.7%[37] - Total comprehensive income for the period was ¥52,381,474.67, down from ¥99,932,407.09, a decrease of about 47.5%[37] - The company reported a basic earnings per share of ¥0.2484, down from ¥0.3608, a decrease of approximately 31.1%[37] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥3,768,529,579.55, a 5.33% increase from the end of the previous year[5] - Total assets at the end of the period stand at RMB 3,768,529,579.55, up from RMB 3,577,825,097.29, reflecting a growth of 5.3%[32] - Total liabilities increased to RMB 1,494,119,020.56 from RMB 1,343,508,907.39, indicating a rise of 11.2%[33] - The company's total equity at the end of the period is RMB 2,274,410,558.99, compared to RMB 2,234,316,189.90 at the beginning, showing a slight increase of 1.8%[33] Cash Flow - The company's cash flow from operating activities showed a net outflow of ¥100,257,427.66, a decrease of 44.42% compared to the previous year[5] - Cash flow from operating activities showed a net outflow of ¥100,257,427.66, worsening from a net outflow of ¥69,419,142.29 in the previous period[38] - Cash and cash equivalents at the end of the period decreased to ¥107,191,770.34 from ¥154,072,168.36, a decline of approximately 30.4%[40] - Current cash and cash equivalents amount to RMB 130,364,458.21, down from RMB 358,761,920.13 at the beginning of the period, representing a decline of 63.7%[30] - The company received cash from operating activities totaling ¥885,902,233.88, an increase from ¥781,674,655.19 in the previous period[38] - Investment activities resulted in a net cash outflow of ¥66,901,122.77, worsening from a net outflow of ¥32,582,898.37 in the previous period[40] Inventory and Receivables - The company's inventory grew by 60.95% year-to-date, driven by increased demand to fulfill customer orders[14] - Inventory has risen significantly to RMB 895,239,906.22, compared to RMB 556,226,345.69 at the beginning of the period, marking an increase of 60.9%[31] - Accounts receivable increased to RMB 783,300,952.52 from RMB 759,138,216.08, showing a growth of 3.8%[30] - The company has reported a decrease in other receivables from RMB 24,404,776.18 to RMB 33,337,874.64, an increase of 36.7%[31] Research and Development - Research and development expenses increased by 45.39% compared to the same period last year, indicating a focus on innovation[21] - Research and development expenses increased significantly from ¥54,726,566.11 to ¥79,565,899.38, an increase of about 45.2%[36] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 32,041, with the largest shareholder holding 18.75% of the shares[23] - The number of restricted shares held by key shareholders remains unchanged at 13,192,587 shares, with a release date set for January 1, 2026[28] Contract Liabilities - Contract liabilities rose by 109.89% year-to-date, reflecting an increase in advance payments from customers due to order growth[17] Return on Equity - The weighted average return on equity was 0.73%, a slight increase of 0.12% compared to the previous year[5]

Company Overview - Cheng Yi Tong, established on July 22, 2003, and listed on March 19, 2015, is located in Beijing's Daxing District and specializes in providing overall solutions for pharmaceutical and biological industrial automation control systems, as well as the research, production, and sales of rehabilitation medical devices [1][2]. Financial Performance - For the first half of 2025, Cheng Yi Tong reported a revenue of 408 million yuan, a year-on-year decrease of 36.65%, and a net profit attributable to shareholders of 51.18 million yuan, down 38.76% year-on-year [2]. - The company has cumulatively distributed 80.55 million yuan in dividends since its A-share listing, with 39.60 million yuan distributed over the past three years [3]. Stock Performance - As of October 16, Cheng Yi Tong's stock price increased by 2.08% to 20.57 yuan per share, with a total market capitalization of 5.617 billion yuan [1]. - Year-to-date, the stock price has risen by 34.84%, with a 2.03% increase over the last five trading days, a 3.79% decrease over the last 20 days, and a 3.58% increase over the last 60 days [1]. Shareholder Information - As of June 30, 2025, the number of shareholders increased by 11.71% to 32,700, while the average number of circulating shares per person decreased by 10.48% to 7,952 shares [2][3]. - Among the top ten circulating shareholders, Huaxia Leading Stock (001042) ranked eighth with 1.4626 million shares, an increase of 80,400 shares compared to the previous period [3].

Core Viewpoint - The stock price of Chengyitong has shown a year-to-date increase of 28.48%, but has recently experienced declines over various time frames, indicating potential volatility in the market [2]. Group 1: Stock Performance - As of October 14, Chengyitong's stock price decreased by 2.05%, trading at 19.60 CNY per share with a total market capitalization of 5.352 billion CNY [1]. - The stock has declined by 1.85% over the last five trading days, 9.68% over the last 20 days, and 4.34% over the last 60 days [2]. Group 2: Financial Performance - For the first half of 2025, Chengyitong reported a revenue of 408 million CNY, representing a year-on-year decrease of 36.65%, while the net profit attributable to shareholders was 51.18 million CNY, down 38.76% year-on-year [2]. - The company has distributed a total of 80.55 million CNY in dividends since its A-share listing, with 39.60 million CNY distributed over the last three years [3]. Group 3: Business Overview - Chengyitong, established on July 22, 2003, and listed on March 19, 2015, specializes in providing automation control solutions for the pharmaceutical and biotechnology industries, as well as the research, production, and sales of rehabilitation medical devices [2]. - The company's revenue composition includes 54.65% from control systems, 28.89% from rehabilitation medical devices, and 16.47% from system equipment and others [2]. - Chengyitong is categorized under the machinery and equipment industry, specifically in general equipment and other general equipment sectors, with involvement in various concept sectors such as pet economy, traditional Chinese medicine, synthetic biology, multiple births, and elderly care [2]. Group 4: Shareholder Information - As of June 30, 2025, the number of shareholders increased by 11.71% to 32,700, with an average of 7,952 circulating shares per person, a decrease of 10.48% [2]. - Among the top ten circulating shareholders, Huaxia Leading Stock (001042) ranked eighth with 1.4626 million shares, an increase of 80,400 shares compared to the previous period [3].

Core Insights - The rehabilitation equipment industry in China is rapidly growing, with the market size expected to reach approximately 714.6 billion yuan in 2024, an increase of 98.9 billion yuan from 2023 [1][6] - The largest market share within the rehabilitation equipment sector is held by rehabilitation therapy devices at 15%, followed by rehabilitation training devices at 4%, and rehabilitation assessment devices at 1% [6] - The market is projected to grow further, reaching an estimated 815 billion yuan by 2025, driven by an aging population and increasing demand for rehabilitation services [1][6] Industry Definition and Classification - Rehabilitation medical devices are defined as equipment used for the prevention, assessment, treatment, training, or compensation of functional disabilities [3] - The main categories of rehabilitation medical devices include rehabilitation aids, rehabilitation therapy devices, rehabilitation training devices, rehabilitation assessment devices, and other rehabilitation equipment [3] Current Development Status - The rehabilitation equipment market in China is predominantly composed of domestic brands, which account for 97.9% of the market, while imported brands make up about 3% [6] - The industry has seen significant expansion in both market size and application areas due to rapid economic development [6] Industry Chain - The upstream of the rehabilitation equipment industry includes raw materials and software systems, while the midstream involves the manufacturing of rehabilitation devices [8] - The downstream applications primarily serve hospitals, community rehabilitation centers, nursing homes, and other medical institutions catering to populations with functional disabilities [8] Market Environment and Policies - The Chinese government has shown strong support for the rehabilitation equipment industry through various policies aimed at promoting its development, such as the "14th Five-Year" National Health Plan and guidelines for enhancing the welfare of the elderly [11] Competitive Landscape - Major companies in the rehabilitation medical device sector include Yuyue Medical, Kefu Medical, and Xiangyu Medical, with Yuyue Medical leading the market in terms of capital and revenue [12] - The industry exhibits a tiered competitive structure, with leading companies in the first tier and several others in subsequent tiers [12] Future Trends - The rehabilitation equipment industry is expected to experience significant growth opportunities, particularly in home settings, driven by an aging population and increasing chronic disease prevalence [13] - The industry is anticipated to evolve towards high-quality development, supported by technological advancements and favorable government policies [13]

近日公司及子公司使用闲置自有资金在授权范围内购买了理财产品，现将相 关事项公告如下： | 投资主体 | 受托 | 关联 | 产品名称 | 产品 | 委托理财金 | 起息日 | 到期日 | 预期年 化收益 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 方 | 关系 | | 类型 | 额（万元） | | | 率 | | 北京诚益通科技有限 | 农商 | 否 | 欣添鑫 | 现金管 | 500.00 | 2025 年 9 月 2 日 | 2025 年 9 月 10 日 | 1.40% | | 公司 | 银行 | | | 理类 | | | | | | 北京诚益通科技有限 | 农商 | 否 | 天天金 | 现金管 | 500.00 | 2025 年 9 月 3 日 | 2025 年 9 月 11 日 | 1.00% | | 公司 | 银行 | | | 理类 | | | | | | 北京诚益通控制技术 | 兴业 | 否 | 兴银稳添利日盈 | 现金管 | 1000.00 | 2025 年 9 月 3 日 | 2025 年 9 月 12 日 | ...

Investment Rating - The report suggests focusing on companies with "technical barriers + clinical landing" as the dual main lines for investment, recommending attention to medical scene integrators and leaders in invasive technology [4]. Core Insights - The brain-computer interface (BCI) industry is driven by both policy and technology, with a market expected to grow from $1.2 billion in 2019 to $2 billion in 2023, and projected to reach $7.63 billion by 2029, indicating a compound annual growth rate (CAGR) of 17.5% from 2024 to 2029 [3][24]. - The medical sector is currently the most mature application area for BCI, with 31 clinical trials planned in 2024 covering various diseases, and the integration of medical and consumer applications is expected to create a dual growth curve [3][54]. - The domestic industry chain is becoming more self-sufficient, with significant advancements in invasive BCI technologies, and several regions are expected to form industrial clusters [4][27]. Summary by Sections Industry Overview - BCI technology is a frontier field at the intersection of life sciences and information technology, creating interactive systems between the brain and external devices [14][16]. - The global BCI market is projected to grow significantly, with a forecasted market size of $7.63 billion by 2029, reflecting a CAGR of 17.5% from 2024 to 2029 [24][25]. - The industry is currently in a technology validation phase, with active investment activities, particularly in China, where over 200 financing events have occurred, totaling nearly $2 billion [27][29]. Policy Guidance - The Chinese government has issued several policies to support the BCI industry, aiming for technological breakthroughs by 2027 and the establishment of a robust industrial ecosystem by 2030 [42][43]. - The regulatory framework is evolving, with ongoing efforts to ensure safety, effectiveness, and ethical compliance in BCI technology [45][47]. Clinical Situation - Stroke is identified as the primary indication for BCI applications, with a significant patient population in need of rehabilitation solutions [54][59]. - The number of clinical trials related to BCI is increasing, with 31 trials registered in 2024, indicating a growing interest in the clinical potential of BCI technologies [65][66].

Core Insights - The company has established a dual-track strategy for its brain-computer interface (BCI) business, focusing on both invasive and non-invasive approaches [1] Non-Invasive Medical Field - In the non-invasive serious medical sector, the company has launched three prototype rehabilitation devices that integrate BCI technology, currently progressing with registration applications [1] - These devices feature modular designs, supporting synchronous collection of EEG, EMG, and ECG signals, and possess precise coordination capabilities with electrical stimulation systems [1] - The devices are designed for flexibility, supporting 8 to 64 channel expansions, and are compatible with mainstream BCI and medical systems, providing reliable support for basic research, neuro-rehabilitation, and BCI application development [1] Consumer Market - In the non-invasive consumer market, the company plans to launch its first batch of prototypes in the first half of 2025, including a next-generation smart EEG headband [2] - This product integrates a self-developed EEG amplification system and intelligent analysis algorithms, enabling high-precision collection and decoding of EEG signals [2] - The headband includes a gamified cognitive training module that adjusts task difficulty based on EEG responses, enhancing user engagement and training effectiveness in attention and memory [2] Invasive Field - In the invasive field, the company is currently focused on technological reserves, with related research in the experimental stage [2] - The company has initiated the construction of a BCI technology research validation center and an animal experiment center, which are crucial for its strategic layout in the BCI field [2] Research Focus - The BCI technology research validation center will focus on cutting-edge theories, key technologies, new materials, and core components in the BCI field, bridging basic mechanism exploration to engineering applications [3] - The animal experiment center will provide in vivo research and application validation for core BCI technologies, equipped for experiments ranging from small rodents to large mammals [3] Financial Performance - In the first half of 2025, the company reported a revenue of 408 million yuan, a year-on-year decrease of 36.65%, and a net profit attributable to shareholders of 51 million yuan, down 38.76% [3] - Revenue breakdown shows that control systems generated 223 million yuan, down 46.12%; rehabilitation medical devices generated 118 million yuan, down 18.10%; and system equipment and others generated 67 million yuan, down 19.50% [3] Market Positioning - The company is leveraging "Longzhijie" to tap into the rehabilitation medical market, which has a comprehensive product line in physical factor therapy and exercise therapy [4]

Core Viewpoint - Chengyitong (300430) has stated that as of September 19, the pledge ratio of shares held by the controlling shareholder and parties acting in concert is 46.49%, which is within a safe and controllable range, and the liquidation price is relatively low, indicating no risk of forced liquidation [1] Group 1 - The current pledge ratio of shares is 46.49% [1] - The company is monitoring risk situations and will disclose relevant information as required [1] - The liquidation price is at a low level, mitigating the risk of forced liquidation [1]